Finance

Lists
128940:KRX
Hanmi Pharm Co Ltd
â‚©485,000.00
-1.52%
(-7,500.00) 1D
Sep 1, 11:45:24 AM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 128940...
Open
â‚©489,000
High
â‚©495,500
Low
â‚©478,000
Mkt. cap
6.21T
Avg. vol.
142.96K
Volume
50.97K
Dividend
0.41%
Quarterly dividend
â‚©500
Ex-dividend date
Mar 30, 2026
P/E ratio
28.36
52-wk high
â‚©647,000
52-wk low
â‚©288,000
EPS
â‚©17,100
Shares outstanding
12.81M
No. of employees
2K
Open
â‚©489,000
High
â‚©495,500
Low
â‚©478,000
Mkt. cap
6.21T
Avg. vol.
142.96K
Volume
50.97K
Dividend
0.41%
Quarterly dividend
â‚©500
Ex-dividend date
Mar 30, 2026
P/E ratio
28.36
52-wk high
â‚©647,000
52-wk low
â‚©288,000
EPS
â‚©17,100
Shares outstanding
12.81M
No. of employees
2K
News stories
From web sources and news partners
Profile
Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul. Wikipedia
About Hanmi Pharm Co Ltd
CEO-
Employees2.34K
Founded1973
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
362.35B
432.96B
392.93B
467.25B
Cost of goods sold
156.75B
172.48B
175.64B
164.04B
Cost of revenue
156.75B
172.48B
175.64B
164.04B
Research and development expenses
54.65B
51.66B
57.12B
52.08B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
95.88B
125.55B
106.52B
120.03B
Operating expense
153.33B
205.73B
171.55B
179.72B
Total operating expenses
310.08B
378.22B
347.19B
343.76B
Operating income
52.27B
54.74B
45.74B
123.49B
Other non operating income
-1.73B
664.20M
2.62B
-4.88B
EBT including unusual items
52.26B
58.49B
55.38B
120.14B
EBT excluding unusual items
51.55B
57.99B
55.26B
119.61B
Income tax expense
6.85B
4.43B
4.30B
36.06B
Effective tax rate
13.10%
7.58%
7.76%
30.01%
Other operating expenses
-
-
-
-
Net income
40.13B
48.12B
45.49B
83.31B
Net profit margin
11.07%
11.11%
11.58%
17.83%
Earnings per share
-
-
-
-
Interest and investment income
1.67B
2.51B
2.62B
2.77B
Interest expense
-3.94B
-3.65B
-3.41B
-3.35B
Net interest expenses
-2.27B
-1.14B
-783.67M
-588.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
76.84B
80.03B
70.44B
148.58B
Gain or loss from assets sale
-13.32M
-39.36M
3.68M
40.66M
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps